The article informs that FORMA Therapeutics and the University of Oxford have signed a collaboration and license agreement for developing deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases. Topics discussed icnlude role of DUBsin protein and cellular homeostasis; statement of John Davis on the same; and creation of a multiyear research program at the University of Oxford.
Processing Request
No Comments.